Ayvakit (Avapritinib) is a kinase inhibitor used for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon-18 mutation, including PDGFRA D842V mutations.
Dosage: The recommended dosage of Avapritinib is 300 mg orally once daily on an empty stomach, at least 1 hour before and 2 hours after a meal. Continue treatment until the disease is progressive or unacceptable toxicity occurs. Do not make up for a forgotten or missed dose within 8 hours of the next scheduled Avapritinib dose. Do not take an additional dose if vomiting occurs after Avapritinib, but continue with the next scheduled dose.
Side Effects: The most commonly reported avapritinib side effects (incidence ≥ 20%) include:
- decreased appetite
- hair color changes
- increased lacrimation
- abdominal pain
- cognitive impairment
Warnings and Precautions:
- Patients with avapritinib drug should contact their health specialist immediately if experiencing neurological signs and symptoms that may be associated with intracranial hemorrhage.
- Pregnancy status should be verified of females of reproductive potential prior to initiating therapy with avapritinib 300 mg. It can cause fetal harm when administered to pregnant women.
- Women should not breastfeed during treatment with avapritinib and for 2 weeks following the final dose.
- Patients and caretakers should notify their health specialist if they experience new or worsening CNS symptoms during therapy with avapritinib tablets. Patients should not drive/operate hazardous machinery if they are experiencing CNS adverse reactions.